Among patients with evaluable tumor tissue, median AXL expression (percentage of AXL-positive tumor cells) at baseline ranged from 1.0% to 5.5% in the NSCLC cohorts and 10.0% to 15.0% in the melanoma cohorts; this was 68.8% in the sarcoma cohort, 1.0% in the mixed solid tumors cohort that received prior PD-1/PD-L1 inhibitor treatment, and 5.0% in the ovarian cancer cohort. Here, AXL is linked to non-small cell lung carcinoma.